Home/Soleno Therapeutics/Mark Hahn

MH

Mark Hahn

Board Member

Soleno Therapeutics

Therapeutic Areas

Rare Genetic Disorders Genetic Obesity Disorders Prader-Willi Syndrome

Soleno Therapeutics Pipeline

Drug	Indication	Phase
VYKAT XR (setmelanotide)	Hyperphagia in Prader-Willi Syndrome	Marketed
Setmelanotide	Bardet-Biedl Syndrome / Alström Syndrome	Phase 3

Leadership Team at Soleno Therapeutics

Anish Bhatnagar, MD

Chairman of the Board and Chief Executive Officer

Lauren Budesheim

Senior Vice President, People

Neil M. Cowen, PhD, MBA

Senior Vice President, New Product Planning

Dawn Carter Bir

View full Soleno Therapeutics profile